Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    63,309.13
    +595.71 (+0.95%)
     

  • CMC Crypto 200

    1,373.19
    +60.56 (+4.61%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • Dow

    37,986.40
    +211.02 (+0.56%)
     

  • Nasdaq

    15,282.01
    -319.49 (-2.05%)
     

  • Gold

    2,406.70
    +8.70 (+0.36%)
     

  • Crude Oil

    83.24
    +0.51 (+0.62%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

The Zacks Analyst Blog Highlights: GlaxoSmithKline, NewLink Genetics, Allergan, Inovio Pharmaceuticals and BioCryst Pharmaceuticals

Zacks Equity Research

For Immediate Release

Chicago, IL – October 20, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the GlaxoSmithKline (GSK-Free Report), NewLink Genetics Corp. (NLNK-Free Report), Allergan, Inc. (AGN-Free Report), Inovio Pharmaceuticals, Inc. (INO-Free Report) and BioCryst Pharmaceuticals, Inc. (BCRX-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Healthcare Stocks in Focus on Ebola Fears

Ebola virus disease fears have intensified as a second nurse at Texas Presbyterian Hospital was tested positive for Ebola, as per preliminary tests. The nurse provided care to the index patient (Thomas Eric Duncan) who later died of the disease. What is concerning is that the nurse traveled through an airline when she may have been already suffering from Ebola, which in turn could have put other passengers and those in contact with them at risk.

The WHO has declared the Ebola epidemic a public health emergency of international concern. As per the Centers for Disease Control and Prevention (CDC) reports, the current outbreak of the disease has affected almost nine thousand people worldwide with Sierra Leone, Liberia and Guinea being the worst affected. Ebola has a high fatality rate of around 50% and approximately half of the nine thousand patients affected are already dead.

Fears about the deadly virus coupled with the lack of any approved treatment for Ebola brings the spotlight on companies researching an Ebola vaccine or treatment.

Companies in Focus

Currently, all the Ebola candidates are in the early (preclinical or phase I) stages of development.

The U.S. government bodies like the National Institutes of Health's (:NIH) National Institute of Allergy and Infectious Diseases, the Department of Defense's Defense Threat Reduction Agency (:DTRA) and the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority are working closely and providing support as well as funding to the companies developing vaccines/treatments targeting Ebola. While GlaxoSmithKline (GSK-Free Report) is collaborating with the NIH, NewLink Genetics Corp. (NLNK-Free Report) is working with DTRA to develop an Ebola vaccine.

Several companies are developing candidates for Ebola including Allergan, Inc. (AGN-Free Report) which has ZMapp in preclinical stage. Inovio Pharmaceuticals, Inc. (INO-Free Report) and GeneOne Life Science Inc. intend to start the human trial on Ebola vaccine in the first half of 2015 while BioCryst Pharmaceuticals, Inc.’s (BCRX-Free Report) candidate BCX4430 is in the preclinical stage.

The Way Forward

Although authorities are working to control the outbreak of this contagious disease, fears of the Ebola outbreak escalating to pandemic status remain. The FDA is working to expedite the approval process for these Ebola candidates. In view of these factors, we believe investors will remain glued on Ebola vaccine/treatment related updates and companies working on Ebola therapies stand to make the most of it.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on GSK - FREE
Get the full Report on NLNK - FREE
Get the full Report on AGN - FREE
Get the full Report on INO - FREE
Get the full Report on BCRX - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Read the analyst report on GSK

Read the analyst report on NLNK

Read the analyst report on AGN

Read the analyst report on INO

Read the analyst report on BCRX


Zacks Investment Research